Parsonage-Turner syndrome (PTS) is a peripheral neuropathy involving the brachial plexus very rare in childhood. To date, no cases of PTS after COVID-19 vaccination have been reported in children. We report a case of a 15-year-old boy affected by PTS after the second dose of the BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 vaccine. Parsonage-Turner syndrome (PTS) is a rare peripheral neuropathy involving the brachial plexus characterized by sudden onset pain affecting the upper extremity associated with muscle weakness. With an estimated incidence of 1.64 cases per 100,000 people, 1 PTS usually develops in people aged between 20 and 60 years, being very rare in children.The diagnosis is based on clinical history, physical examination, electrophysiological study, and exclusion of other pathologies. The clinical picture of PTS is very diverse because a large variety of nerves can be affected. Muscle paresis commonly manifests as scapula alata, secondary to paresis of the muscles involved in scapular fixation. 2 Pain is the first symptom in 90% of patients, being the location of pain variable, but in most cases radiated from the cervical spine or shoulder region into the arm. 1 Electrodiagnostic testing is widely used to diagnose PTS. Abnormal sensory potentials, lack of denervation potentials, and abnormal conduction velocities are the most frequent findings.The etiology and pathophysiology of PTS still remain unclear. 3 Recent viral infections, such as herpes simplex virus, Epstein-Barr virus, cytomegalovirus, HIV, hepatitis B virus, and parvovirus B19 infections, have been reported as the probable trigger in 25% of patients with PTS. [4][5][6] Vaccination has been described to precede PTS in 4.3% to 15.5% of cases. 1,5 To date, only a few cases of PTS after COVID-19 vaccination have been reported, none of them in the childhood. [7][8][9][10][11][12][13][14][15] In this study, we report a case of a child affected by PTS after the second dose of COVID-19 vaccination. CaseA 15-year-old boy presented to the clinic because of acute pain and functional impotence in his left shoulder that started 1 week before. Physical examination revealed reduced range of motion for shoulder flexion and abduction because of weakness and pain. He had full flexion and extension of the wrist and fingers as well as hand interosseous muscles. Four weeks earlier, he had received the

Background To investigate the functional outcomes of reverse shoulder arthroplasty (RSA) in acute complex proximal humerus fractures (PHF) in patients with an anatomic greater tuberosity union in comparison to patients with a displaced or resorbed tuberosity. Method: It is a retrospective study with prospective data collection including 32 consecutive PHF with a minimum two-year follow-up treated with RSA. A radiological study and a CT scan were performed specifically for the study. Two shoulder surgeons and a musculoskeletal radiologist assessed the position and union of the greater tuberosity. The functional outcomes were assessed with the Constant-Murley, DASH, ASES and ADLER scores. Results: The mean overall CS was 59.55. In 17 cases, the greater tuberosity healed in an anatomical position. In 15 cases, it was non-anatomical. In 53% of patients, greater tuberosity union was obtained. The CS was 62.76 in the anatomic union group and 55.9 in the non-anatomic union group. No significant differences were observed. No differences were observed in the ASES, DASH and ADLER scores. Conclusion: After RSA for PHF, anatomic greater tuberosity healing was obtained in 53% of patients. The influence of the position and union of the greater tuberosity on the functional results could not be evidenced.